The results from the transcriptional analysis of 298 metastatic urothelial carcinoma samples suggested that the enhanced TGF-β in CAFs was related to poor CD8+ T-cell infiltration within tumor parenchyma and weak response to atezolizumab (79). The gene discussed is TGFB1; the disease is urothelial carcinoma.